Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroprotection by MK-801 in temperature maintained gerbils

C A Hoffman1, C A Boast

  • 1Wyeth-Ayerst Research, Princeton, NJ 08543, USA.

Brain Research Bulletin
|January 1, 1995
PubMed
Summary

Hypothermia confounds drug effects on brain injury. MK-801 shows neuroprotection in gerbils, but only when body temperature is normothermic (36.5°C), not hyperthermic (38.5°C).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantification of Blood Velocity with 4D Digital Subtraction Angiography Using the Shifted Least-Squares Method.

AJNR. American journal of neuroradiology·2018
Same author

The zimmerman award.

Environmental science & technology·2012
Same author

Hydronephrosis due to aberrant vessels.

The West Virginia medical journal·2010
Same author

An unusual symptom complex following transurethral resections.

The Journal of urology·2010
Same author

The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist.

The Journal of pharmacology and experimental therapeutics·2000
Same author

Discovery of a highly potent, functionally-selective muscarinic M1 agonist, WAY-132983 using rational drug design and receptor modelling.

Bioorganic & medicinal chemistry letters·1999

Area of Science:

  • Neuroscience
  • Pharmacology
  • Ischemic Stroke Research

Background:

  • Hypothermia is known to reduce ischemic brain damage.
  • The neuroprotective drug MK-801 can induce hypothermia, complicating the assessment of its effects.
  • Conflicting studies exist on whether MK-801's neuroprotective properties persist when body temperature is controlled.

Purpose of the Study:

  • To evaluate the neuroprotective effects of MK-801 in gerbils under controlled body temperature conditions.
  • To determine if MK-801 confers neuroprotection independently of its hypothermic effects.
  • To investigate the dose-dependency and temperature-sensitivity of MK-801's neuroprotective actions.

Main Methods:

  • Gerbils underwent bilateral carotid occlusion for 5 or 10 minutes.
  • MK-801 was administered intraperitoneally at various doses (3-10 mg/kg).
  • Body temperature was either free-regulating or maintained at hyperthermic (38.5°C) or normothermic (36.5°C) levels.

Main Results:

  • In free-regulating animals, MK-801 (3 mg/kg) showed neuroprotection after 10 min of ischemia, coinciding with significant hypothermia.
  • No neuroprotection was observed with MK-801 (up to 10 mg/kg) at hyperthermic temperatures (38.5°C), even with reduced ischemia.
  • MK-801 (10 mg/kg) significantly reduced brain damage at normothermic temperatures (36.5°C) after 5 min of ischemia.

Conclusions:

  • MK-801 can reduce ischemic brain damage independently of hypothermia, but requires higher doses.
  • The findings suggest that mechanisms beyond NMDA receptor antagonism may contribute to MK-801's neuroprotective effects.
  • Controlled temperature is crucial for accurately assessing drug efficacy in models of ischemic brain injury.

Related Experiment Videos